INTRODUCTION 69
Cystic fibrosis (CF) is a multi-organ system disease associated with mutations in the 70 gene that codes for CF transmembrane conductance regulator (CFTR) protein 71 (5, 14, 26, 33, 43, 48, 53, 60) . The majority of wild-type CFTR -and virtually all mutant F508del 72 CFTR -are degraded prior to reaching the cell surface (5, 14, 26, 33, 43, 48, 53, 60) . Recent 73 studies have shown that inhibiting CFTR ubiquitination and proteosomal degradation with 74 chemical and pharmacological chaperones can promote membrane expression of mutant 75
F508del-CFTR in the cell membrane (1,17,25,41,55.57,58) . As a result, there is substantial 76 interest in developing compounds that promote F508del CFTR incorporation into the 77 plasma membranes of CF patients (48, 53) . 78
Molecular chaperones facilitate CFTR folding and suppress its aggregation. They 79 also play a role in recognizing misfolded CFTR and signaling its degradation, thus 80 determining the early fate of the misfolded protein (1,17,25,41,55.57,58) . Molecular 81 chaperones and co-chaperones are involved in CFTR folding and cell-surface expression 82 (6, 27, 47, 48, 64) . Hsp70/Hsc70, Hdj-2, Hsp90, cysteine string protein, calnexin, 83 Hsp70/Hsp90 organizing protein (Hop) -or stress-induced phosphoprotein 1 (Stip1) -are 84 among the proteins that assist in CFTR folding (44, 62, 63, 64, 65) . The interaction of CFTR 85 with Hsc70 -coupled to its co-chaperone CHIP -leads to degradation of CFTR through the 86 ubiquitin-proteosome pathway (61) . 87
The endogenous S-nitrosothiol, S-nitrosoglutathione (GSNO), increases the 88 maturation and function of CFTR in human airway epithelial cells (2, 11, 29, 37, 52, 54, (62) (63) (64) (65) . 89
GSNO and other S-nitrosothiols have additional beneficial effects on airway function, 90
including relaxation of airway smooth muscle, improvement of ciliary motility, inhibition of 91 amiloride-sensitive sodium transport, and prevention of bacterial and viral infections 92 (3, 16, (19) (20) (21) (22) (23) 28, 30, 31, 32, 36, 38, 40, (45) (46) 59) . Therefore, since S-nitrosothiol levels are low 93 in the CF in the CF airway (24), chronic replacement therapy with a low dose of inhaled 94 GSNO has been proposed as a potential therapy for CF patients (54) . 95
Previous work demonstrates that GSNO is both a corrector and a potentiator: it both 96 activates CFTR (11,37) and redirects F508del-CFTR to the cell membrane (2, 29, 37, 62) . 97
The mechanisms involved in its corrector function are complex, (36, 61, 62, 63) , but the 98 principal effect requires S-nitrosylation of Stip1 at cysteine 403. This signal targets Stip1 99 for degradation. Loss of Stip 1 prevents F508del-CFTR degradation and permits its 100 maturation and cell surface expression (37). 101
In addition, several lines of evidence suggest that enhanced GSNO metabolism may 102 be relevant to CF (2, 11, 24, 29, 37, 52, (62) (63) (64) (65) . S-nitrosoglutathione reductase, also known as 103 glutathione-dependent formaldehyde dehydrogenase, catalyzes the degradation of GSNO 104 and regulates tissue level of S-nitrosothiols and S-nitrosylated proteins (35, 39, 47) . We 105 hypothesized that GSNO reductase activity increases in airway epithelial cells of CF 106 patients, and that decreased airway levels of S-nitrosothiols in CF (24) are due, at least in 107 part, to upregulation of GSNO reductase. The present study demonstrates that (1) The enzymatic activity of GSNO reductase was measured as described previously (35, 47) . 207
Briefly, cell lysates were incubated with NADH in reaction buffer (20 mM Tris HCl, pH 8.0) 208 and 0.5 mM EDTA containing 0 or 100 μM GSNO at room temperature. NADH 209 fluorescence (absorption at 340 nm and emission at 455 mm) was measured over time in a 210
FLUOstar Omega (BMG Labtech, Inc., Offenberg, Germany). The concentrations of NADH 211 in cell samples were determined using a standard curve (35, 47) . 212
Immunohistochemistry of GSNO Reductase in CFBE41o
-Cells 213 were washed (x2 for 15 min) in blocking solution with 0.1%NGS, stained with Dapi for 237 nuclear staining, followed by washing in DPBS. As negative control an isotype control for 238 mouse and rabbit (BD Pharmingen, USA) were respectively used at the same 239 concentration as Hop and GSNO reductase primary antibodies followed by labeling with the 240 respective secondary antibodies. The cells were mounted and visualized using 63x NA1.4 241 oil immersion lens on Leica TCS SP5 for laser scanning confocal microscopy. The white 242 light lasers of 488nm (20%) and 568nm (65%) were used for excitation of Hop-Alexa488 243 (Emission 500-550nm) and GSNO reductase-Alexa568 (Emission 580-640nm), 244 respectively. Identical imaging parameters were used for isotype controls. blot analysis using rabbit polyclonal anti-GSNO reductase antibody. 255
Statistics 256
We conducted two-way ANOVA for each experiment. In each model, we included the main 257 effects of treatment and band, and their interaction. The statistical analyses were 258 performed with SAS 9.1 (SAS Institute Inc., Cary, NC Figure 1A and B, n=3, p<0.05). Furthermore, GSNO reductase 268 activity was elevated approximately two-fold in the mutant CFBE41o 
GSNO Reductase Expression Level Differences in Primary Human Bronchial Epithelial 272

Cells Expressing Wild-Type and Mutant F508del-CFTR 273
GSNO reductase protein expression levels were elevated approximately two-fold in two of 274 the three mutant F508del CFTR donors. The third clone did not show any changes when 275 compared to primary wild type human bronchial epithelial cells ( Figure 1D and E) . 276
Cellular Co-localization of GSNO Reductase and Stip1 in CFBE41o -Cells 277
We have demonstrated cellular co-localization of GSNO reductase and Stip1 in human 278 bronchial airway epithelial cells by immunoprecipitation ( Figure 2C , n=2) and we showed 279 that exogenous GSNO can reduce excess GSNO reductase to wild type levels ( Figure 2C) . 280
In addition, our confocal microscopy results suggest that GSNO reductase is present in 281
CFBE41o
cells and co-localizes with Stip1 ( Figure 2A ). Isotope controls were negative 282 ( Figure 2B ). Taken together, these data reveal that GSNO reductase and co-chaperone 283
Stip1 interact directly in CFBE41o -cells. 284
GSNO Reductase Knockdown with siRNA Increases Expression of F508del-CFTR 285
To confirm the role of GSNO reductase in F508del CFTR maturation, we knocked out 286 endogenous GSNO reductase by transfected mutant CFBE41o -cells with 50, 75, and 100 287 nM of GSNO reductase siRNA. After 48 hours of transfection with 50 nM of siRNA, 288 duplexes for GSNO reductase minimally decreased endogenous GSNO reductase levels. 289 Also, there was no effect on CFTR levels. However, at concentration of 100 nM of siRNA 290 duplexes for GSNO reductase, endogenous levels of GSNO reductase expression was 291 markedly decreased which produced a significant increase in levels of immature and fully 
GSNO Reductase Inhibits Maturation of CFTR and GSNO Reductase Inhibitor Reverses 296 this Effect 297
Increasing endogenous GSNO reductase levels by transfection with FLAG-tagged GSNO 298 reductase (2 µM; 48 hours) caused an effective decrease (2.2-fold) in immature band (band 299 B) and 1.8-fold decrease in mature band (band C) of CFTR ( Figure 4 ; lane 3) compared to 300 control. However, the GSNO reductase inhibitor, C3 (1 µM; 4h), effectively reversed the 301 inhibitory effects of FLAG-tagged GSNO reductase, therefore causing an increase of 302 immature band by 2.1-fold (P < 0.02) and an increase of mature band by 2.0-fold (P < 0.02) 303 of CFTR in wild-type CFBE41o 5, 14, 26, 33, 43, 48, 53, 60) . The most common mutation associated with CF, F508del-CFTR, 309 is a single amino acid, phenylalanine deletion (5, 14, 48) . The majority of wild-type CFTR 310
proteins -and virtually all F508del-CFTR proteins -are degraded before reaching the cell 311 surface (26, 33, 43, 53 F508del-CFTR, making it potentially functional in plasma membranes (6, 15, 27, 49, 50, 66) ; 316
however, their precise mechanisms of action are unknown. 317
One class of F508del-CFTR correctors for which the mechanism of action is 318 established is the class of compounds known as S-nitrosothiols (2, 29, 37, (62) (63) (64) (65) . Note in 319 this regard that GSNO and other S-nitrosothiol species in this class are in transnitrosation 320 equilibria in vivo. S-nitrosothiols increase CFTR maturation by S-nitrosylation of specific 321 cysteine residues of molecular chaperones involved in regulating CFTR biogenesis and 322 membrane trafficking. These include cysteine string protein (Csp), heat shock cognate 70 323 (Hsc70), and Stip1 (7, 10, 13, 37, 42, 56, 61, 63) . Co-chaperone Stip1 is a critical component 324 for efficient maturation of steroid receptor complexes (8, 9, 12) . Stip1 provides an important 325 link between Hsp70 and Hsp90 and coordinates Hsp actions in folding protein substrates. 326
Stip1 also plays an active role in functional maturation of Stip1-complexes (9). The 327 molecular structure of Stip1 has two reduced cysteines (C26 and C403) located in tyrosine-328 cysteine "YC" S-nitrosylation motifs (8). We have reported that Stip1 plays a central role in 329 the mechanism by which S-nitrosothiols increase CFTR maturation (37): it co-330 immunoprecipitates with CFTR (37), and its expression, free and bonded to CFTR, is 331 decreased by GSNO through an effect of GSNO (and other S-nitrosothiols) to S-nitrosylate 332 C403, targeting Stip1 for degradation and permitting CFTR maturation (37). Indeed, Stip1 333 siRNA also enhances CFTR maturation. 334
In addition, S-nitrosothiols have CFTR-independent beneficial effects that may 335 promote airway function, including relaxing airway smooth muscle, improving ciliary 336 motility, inhibiting amiloride-sensitive sodium transport and preventing bacterial and viral 337 infections (3,16,19-23,,28,30,31,34,36,37,40,59) . Because levels of S-nitrosothiols are low 338 in the CF airway (24), chronic therapy with inhaled GSNO is therefore appealing as a 339 potential therapy for patients carrying F508del-CFTR mutation (54). Dose-response 340 experiments in monolayer cell cultures indicate that 5-10 μM of S-nitrosothiols may be 341 optimal for increase F508del-CFTR function (52, 62, 63, 65) . Further, we found that GSNO reductase knockdown results in enhanced CFTR 367 maturation and decreased endogenous Stip1 expression. Indeed, we found that GSNO 368 reductase and Stip1 co-localize and directly interact in CFBE41o -cells ( Figure 2C) . 369
Because S-nitrosylation of Stip1 causes decreased interaction between Stip1 and CFTR -370 permitting CFTR maturation (37) -denitrosylation of Stip1 by GSNO reductase inhibits 371
F508del-CFTR correction 372
We determined that increasing expression of endogenous GSNO reductase led to 373 lower CFTR expression. We found that cells transfected with FLAG-tagged GSNO 374 reductase had significantly decreased maturation of CFTR, and that GSNO reductase 375 inhibition effectively reversed the effect of GSNO reductase on CFTR expression. It is 376 important to note that inhibitors of GSNO reductase are in development for treatment of 377 asthma and cystic fibrosis (3, 47, 51) . Our current results support the notion that 378 augmented GSNO reductase activity increases CFTR maturation in full-thickness airway 379 epithelial cultures cells. These findings will help to optimize the dosing of S-nitrosothiols 380 and GSNO reductase inhibitors that potentially could be used as F508del-CFTR correctors. 381
They may also provide a marker (increased GSNO reductase activity) for those CF patients 382 most likely to benefit from GSNO reductase inhibition. 383
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